ERC Consolidator Grant · 2022
Targeting long non-coding RNAs for novel treatment strategies in vascular diseases
The perception that RNAs are passive carriers of genetic information has been overturned. Due to the diverse targeting abilities and extensive research in RNA modification and delivery systems, nucleic acid-based therapies have emerged as suitable treatment options for many diseases. Targeting RNAs offers opportunities to modulate numerous cellular processes, including those linked to the large portion of ‘undruggable’ proteins. Currently approved protein-targeted therapies interact with <700 gene products, meaning that only 0.05% of the human genome is presently utilized for treatment. On the contrary, a large fraction of the human genome (>70%) is transcribed into non-coding RNAs. Humans…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.
← All labs at University Hospital Munich \Klinikum rechts der Isar\